Publication | Closed Access
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
1.8K
Citations
33
References
2005
Year
Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
| Year | Citations | |
|---|---|---|
Page 1
Page 1